Mesenchymal stromal cells (MSCs) and chimeric antigen receptor (CAR)‐T cells are two
core elements in cell therapy procedures. MSCs have significant immunomodulatory effects …

ABSTRACT Introduction: Mesenchymal stromal cells (MSCs) are non-hematopoietic
progenitor cells that have been exploited as vehicles for cell-based cancer therapy. The …

Mesenchymal stem cells (MSC) have been explored as a new clinically relevant cell type to
repair injured tissue. A growing corpus of studies have highlighted two important aspects of …

Cytotoxic T lymphocytes (cytotoxic T cells, CTLs) are an immune effector cell population that
can mediate specific immune responses against cancer. Based on this concept, tumor …

Stem/progenitor cell‐based therapeutic approach in clinical practice has been an elusive
dream in medical sciences, and improvement of stem cell homing is one of major challenges …

Mesenchymal stromal cells (MSCs) are currently being investigated for use in a wide variety
of clinical applications. For most of these applications, systemic delivery of the cells is …

Mesenchymal stromal cells (MSC) represent a type of multipotent cells that can differentiate
to various mesenchymal lineages. MSC can be isolated from different tissues and require ex …

Mesenchymal stromal cells (MSCs) have been widely investigated for their therapeutic
potential in regenerative medicine, owing to their ability to home damaged tissue and serve …

Mesenchymal stromal cells (MSCs) have come into focus for an increasing number of
cellular therapies. Since most clinical protocols use intravenous application of MSCs, it has …

Mesenchymal stem cells (MSCs) were originally defined by their capacity to differentiate into
various connective tissue lineages as well as support hematopoiesis in vitro via the …